- Home
- CAI vs NAMS Comparison
CAI vs NAMS Comparison
Compare CAI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | NAMS |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Netherlands |
| Employees | 1846 | 100 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CAI | NAMS |
|---|---|---|
| Price | $17.31 | $35.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $30.91 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.24 | $17.96 |
| Revenue Next Year | $22.32 | $540.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.19 | $20.53 |
| 52 Week High | $42.50 | $42.21 |
Technical Indicators
Market Signals| Indicator | CAI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 60.82 |
| Support Level | $14.19 | $33.83 |
| Resistance Level | $19.83 | $37.27 |
| Average True Range (ATR) | 1.16 | 1.72 |
| MACD | -0.10 | 0.59 |
| Stochastic Oscillator | 11.11 | 77.83 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.